Post-translational modifications by the Small Ubiquitin-like Modifier (SUMO) are essential for many eukaryotic cellular functions. Several large-scale experimental datasets and sequence-based predictions exist that identify SUMOylated proteins. However, the overlap between these datasets is small, suggesting many false positives with low functional relevance. Therefore, we applied machine learning techniques to a diverse set of large-scale SUMOylation studies combined with protein characteristics such as cellular function and protein-protein interactions, to provide integrated SUMO predictions for human and yeast cells (iSUMO).
Introduction
The covalent attachment of Small Ubiquitin-like Modifier (SUMO) is, based on its common occurrence and wide array of functions in eukaryotic cells, one of the most important post-translational modifications.
SUMOylation has been studied from numerous perspectives since its discovery in 1997 (1). It is widely conserved across eukaryotes (2-4), and in many cases essential for the organismal viability (5, 6).
SUMOylation resembles ubiquitination in terms of structure, enzymatic pathway, and it has a broad functional spectrum, ranging from chromatin organization (7), DNA damage repair (8), regulation of transcription (9), ribosome biogenesis (10), messenger RNA (mRNA) processing (11, 12) , nucleuscytoplasm transport (13), to protein localization (14), proteolysis (where it cross-talks with ubiquitination)(15), stress responses (16) and other functions (17).
Several computational approaches exist that predict SUMOylation based on the conserved amino acid sequence motif Ψ -K-X-D/E, where Ψ is a hydrophobic residue, K is the lysine being modified, X is any amino acid, and D/E is an acidic residue (18-21). However, these sequence-based predictions have many false positives and false negatives: when comparing them to experimental data, the intersection is only small.
For example, half of the human proteins contain the above SUMOylation motif in their sequence, but the modification is verified for only a small fraction. In addition, recent experimental data suggests that SUMOylation may also act on motifs other than the one described above (22), highlighting the need for methods that move beyond use of sequence alone.
Several experimental methods have been developed to identify SUMO-targets. For example, immunoprecipitation using antibodies against SUMOylated proteins reveals SUMO conjugation with high confidence (23), but the assay only works with a small number of proteins at a time. In comparison, mass spectrometry based methods sample a large fraction of the proteome and have by now identified thousands of SUMO targets in yeast and human (Figure 1) . However, it is often unclear what the false-positive and false-negative identification rates of these approaches are. For example, a recent and in-depth screen of human SUMOylation targets using advanced technology identified only 1,606 proteins (22) , and overlap between this and other studies is small (Figure 1) . In comparison, when using sequence-based predictions, many more SUMO-targets have been identified, e.g. 8,272 of 17,741 human proteins (47%) are predicted to have a SUMOylation motif in their sequence.
Overall, these findings suggest that our current computational and experimental methods contain large numbers of both false positives and negatives, without high confidence in their functional relevance.
Therefore, we present an approach to integrate various dataset to provide a comprehensive picture of SUMOylation that distinguishes between functional and non-functional SUMOylation events. We developed iSUMO that integrates protein sequence and functional annotations into a comprehensive prediction strategy.
We describe iSUMO's approach, its validation, and application to both yeast and human for a genome-wide assessment of SUMOylation.
Materials and Methods

Training data sets of experimentally observed SUMOylated proteins
We assembled the results from 14 and six large-scale, experimental studies in human (24-37) and yeast (38) (39) (40) (41) (42) (43) , respectively, which mapped SUMOylated proteins using mass spectrometry. Figure 1 summarizes the relationships between the datasets, and detailed description of the data can be found in Supplementary Tables S1. We obtained a total of 1,860 and 555 distinct human and yeast proteins, respectively.
For the Gene Ontology (GO) enrichment analysis, the human reference proteome was downloaded from European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI) release 2014_04, based on Universal Protein Resource (UniProt) release 2014_04, Ensembl release 75, and Ensembl Genome release 21 (http://www.ebi.ac.uk/reference_proteomes). The yeast reference proteome data was from Saccharomyces Genome Database (SGD), based on S288c reference genome release R64-1-1. We then filtered both reference proteomes to contain only one protein per gene, restricting the protein status in UniProt to 'reviewed'. The filtering resulted in 22,242 and 6,619 distinct genes/proteins for human and yeast, respectively.
To integrate the various datasets, we adopted different gene identifiers and filtered the reference lists to retain only the genes and proteins that had unique identity across the combination of Ensembl Gene ID, National Center for Biotechnology Information (NCBI) Gene ID, and UniProt Knowledge Base (UniProtKB) Accession ID. Also, we restricted the proteins' review scores in UniProtKB to five out of five, thus ensuring reliability of the gene annotations. As a result, the final datasets comprised 17,741 and 6,609 human and yeast proteins, respectively. Of these proteins, 1,742 and 530 were labeled as experimentally observed SUMOylated, respectively (Figure 1) .
Sequence-based prediction of protein SUMOylation
For genome-wide prediction of SUMOylation based on protein sequence, we used the Group-based Prediction System-SUMO (GPS-SUMO) (19, 44) to predict both canonical SUMOylation motifs and SUMO-decision nodes and prediction nodes, connected in alternating fashion. An instance traverses all the possible nodes that satisfy feature values and sums up the prediction scores as the output. In the LADTree model, the output score is between 0 and 1, and in our case, a prediction score of 1 represents 'SUMOylated', while 0 represents a 'non-SUMOylated' protein. As training labels were strongly biased towards non-SUMOylated proteins, we used a 'split and recombine' strategy to balance true positives and negatives. We randomly partitioned human non-SUMOylated proteins into nine non-overlapping subsets, each of the similar size of the set of SUMOylated proteins, and learned the model nine times independently, using the method described above. The prediction scores from these models were averages as described in the Results section.
For yeast, every step is carried out in the same way, except we divided the negative examples into eleven random subsets.
Each model from the 'split and recombine' strategy was built and evaluated using ten-fold cross-validation using ten independent random re-samplings of the training data. In other words, after balancing the original data with respect to positive and negative instances, we applied bagging LADTree to each of the balanced partition of the data and used the average prediction scores as the final output. A representative example tree is shown in Figure 4 .
We recorded the average measures of accuracy, precision, recall, and receiver operating characteristics (ROC) using the ROCR package(55). We compared the proteins' prediction scores given by each model to ensure agreement across sub-datasets. All R or Python scripts are available upon request; input and output data files are provided in the Supplementary Material.
Estimation of the total number of SUMylated proteins
This calculation is independent of iSUMO predictions, as it only takes experimental datasets into account. In brief, the method uses an approximation of the hypergeometric distribution to estimate the total size of the population (SUMO-'ome') from the sizes and intersections of two 'samples' (experiments) drawn from the population. We adapted this approach from reference (56), in which the total number of protein-protein interactions was estimated from several large-scale data. When we estimated the total number of SUMOylated proteins in the entire human genome, the pairwise analysis of all 14 human datasets provided a median of 1,241 and a mean of 1,610 SUMOylated proteins.
Results
Integrating large-scale studies of SUMOylated proteome
To obtain a comprehensive training dataset of true-positive SUMOylated proteins, we integrated 14 and six large-scale, experimental studies for human and yeast, respectively (Figure 1 ). In human, these studies identified between eleven to 841 proteins, and a total of 1,862 SUMO targets. About half (45%) of these proteins were identified by two or more studies. In yeast, only one third (30%) of the 555 total SUMOylated proteins were identified by more than one study. The lack of overlap between individual studies indicates that the individual studies suggests that many have false-positive identifications which are not biologically functional. Table 1 shows representative, highly significant Gene Ontology (GO) enrichments for both the human and yeast SUMOylated proteins at an FDR cutoff of E-40. The complete results are in the Supplementary Tables. Both human and yeast were enriched in functions related to DNA use and metabolism, including chromatin organization, DNA damage response, mitosis cell cycle, and transcription; cellular compartments including nucleus, nucleoplasm, nuclear body, and nucleolus. These functions are consistent with our current understanding of SUMOylation's important role in gene expression regulation (57, 58) . Interestingly, we found more than half of the 163 proteins that work in viral transcription annotated as SUMOylated, which is consistent with the notion that viruses take advantage of host cell SUMOylation to optimize viral gene expression (59).
SUMOylated human and yeast proteins primarily have nucleic acid related functions
In addition, GO terms relating to RNA use and metabolism were highly enriched, often even more significantly than those concerning DNA (Table 1) . These functions included RNA processing, translation elongation and termination, cellular compartments like nucleolus, ribonucleoprotein complex, spliceosomal complex, cytoplasmic ribosomes, and molecular functions like RNA binding -all link to RNA functions at various levels. The function enrichment towards RNA metabolism was even stronger in human than in yeast, perhaps due to the expanded role of post-transcriptional regulation, e.g. via splicing, in human.
Further, SUMOylated proteins were preferably part of protein complexes, consistent with the hypothesis that SUMOylation helps with complex assembly and stabilization of protein-protein interactions (60).
SUMOylation of protein complexes is discussed more in detail below ( Table 2) . We also observed enriched functions which have so far received less attention in connection with SUMOylation. For example, threequarters (86/110) of the human proteins annotated as part of the signal recognition particle and its co-translational protein targeting to membranes are SUMOylated -which has, to the best of our knowledge, not yet been reported in literature. (Figure 2) , we observed, with the exception of the mitochondrial ribosome, that the number of RNA-binding subunits and the number of SUMOylated subunits were strongly correlated. The probability to be SUMOylated was therefore linked to the number of protein interactions and the complex size.
Predicting SUMOylation is improved by integration of diverse annotations
The wide range of characteristics of SUMOylated proteins highlight the need for tools that include more than sequence information to predict SUMOylation. We developed such a tool, called iSUMO, employing machine learning algorithms, i.e. boosting tree-based predictive models. This group of algorithms performs well with binary attributes which comprise much of our training set. iSUMO integrates a total of 105 and 77 attributes for human and yeast, respectively, which are listed in the Supplementary Tables. These attributes include the function biases discussed above, information on protein interactions, and sequence-based predictions derived from the GPS-SUMO tool(19). Since the training set (Figure 1 ) contains ten-fold more negatives than positives, i.e. non-SUMOylated and SUMOylated proteins, respectively, we employed a 'split and recombine' strategy that randomly split the set of negatives into multiple subsets of the same size as the positives, and then averaged over the resulting separate training results. Training and learning was carried out using bagging multiple LADTrees (61) as this algorithm outperformed other algorithms that we tested (not shown). For each dataset with equal instances of positives and negatives, we fitted a Bagging LADTree using the WEKA environment(54). To evaluate the success of the learning, we then performed ten-fold cross-validation which, in ten iterations, used 90% and 10% of the data for training and testing, respectively.
The results of this testing were then presented in Receiver-Operator-Curves (ROC).
Overall, iSUMO showed a substantial improvement over predictions based on sequence alone (Figure 2 
Protein-protein interactions are predictive of SUMOylation
Next, we analyzed the iSUMO models for attributes that are highly predictive across separate round of learning (Figure 3) . A representative example tree is shown in Figure 4 . As the underlying model was a decision tree, the level of 'depth' at which an attribute occurred was indicative of its importance: the smaller the depth, the more important the attribute.
The decision tree in Figure 4 shows the 'isBioGridInteractor' attribute which describes the protein having at least one protein interaction partner listed in the BioGrid database(47-50). This attribute nearly always occurred at depth 1 which confirmed the importance of protein-protein interactions when predicting SUMOylation events. A SUMOylated human protein is highly likely to interact with other proteins -and vice versa.
The next most common attribute was 'localization to exosomes' (Figure 3) . This annotation is non-trivial to interpret, since two types of exosomes exist with very different functions. In one definition, an exosome is a multiprotein complex that exists in the cytosol and nucleus, and degrades RNA using different endo-and exonucleases. This complex therefore has many RNA-binding proteins which would explain the high degree of SUMOylation. In the second use, exosomes are membrane-enclosed microvesicles that are secreted and contain miRNA, RNA, and proteins. Recent work has shown that the RNA-binding protein hnRNPA2B1, which is responsible for sorting miRNAs into the exosome vesicles, is SUMOylated (62).
Other common attributes with high predictive power included 'RNA binding', nucleolus', 'nucleoplasm', 'chromosome', 'macromolecule complex subunit organization', 'isCORUMsubunit', and 'ancestry' (Figure   3) . Notably, being part of a protein complex ('isCORUMsubunit') is different from a simple protein-protein interaction ('isBioGridInteractor'), as not all protein-protein interactions necessarily lead to stable complexes.
In comparison, the most common attribute in the yeast models was the sequence-based SUMO prediction 'countTypeIpred', which is the number of covalent SUMO modification motif predicted within the protein sequence using a software tool (19, 44) . This observation suggested that sequence-based predictions in yeast proteins are quite successful, but SUMOylation may have acquired more complex roles in humans that are not encoded in sequence.
Validation and application of iSUMO predictions
To validate the iSUMO predictions independently, we compared the results to a publication by Hendriks et al.
which reports SUMOylation sites for >1,600 human proteins (22). This study was not part of iSUMO's training dataset. Figure 5 shows the kernel densities of the iSUMO prediction scores for all human proteins, separated into proteins observed by Hendriks et al. and those not observed in the independent study. The higher the iSUMO prediction score, the higher the fraction of proteins confirmed by Hendriks et al. For example, at an iSUMO prediction score cutoff of 0.77 (5% FPR), of the 1,596 proteins predicted to be SUMOylated, one third (458) were validated by the independent dataset. Table 3 lists ten human proteins with the highest iSUMO prediction scores, but which were not reported in the original 14 training datasets. Four of the ten proteins were validated by independent large-scale studies (Table 3) , three are listed in the recent study by Hendriks et al. (PSMA1, DGCR8, NUFIP1)(22). Seven proteins are also ubiquitinated -and given that the ubiquitin and SUMO often co-occur, this observation strengthens the prediction. One of highly predicted proteins is microprocessor complex subunit DGCR8, an RNA-binding component of the microprocessor complex which is responsible for cleaving pri-miRNA to precursor miRNA. DGCR8's SUMOylation has recently been confirmed in a targeted study: SUMO at lysine 707 stabilizes the protein by preventing ubiquitination and subsequent degradation through ubiquitin proteosomal system (63). The same study also showed that SUMO affects DGCR8's affinity to pri-miRNAs, ensuring their repression of the mRNA targets.
Discussion
Despite the availability of several large-scale experimental datasets that identify SUMOylated proteins in human and yeast cells, the studies only partially intersect with each other, suggesting many false positive identifications (Figure 1) . To predict the true-positive SUMOylation events that are likely biologically functional, we used 14 and 6 large-scale studies from human and yeast, respectively, and integrated the data with sequence-based SUMOylation predictions and other protein characteristics. Using these overrepresented characteristics and the experimental training data, we constructed iSUMO, an integrated search engine which predicts about five times more proteins in the training data than sequence-based predictions alone (at 5% false positive rate) -and one third of these predictions are validated by an independent, high-quality study that has been published recently ( Figure 5 ).
iSUMO predicted a total of 1,596 SUMO targets in human -a number which is very close to the total size of the human SUMO-'ome' which we estimated based on a published method that analyzes the overlap between different experimental datasets (56). This similarity in numbers suggests that we are perhaps close to having identified the entirety of SUMOylated proteins, and that iSUMO balances prediction depth (coverage) with accuracy.
The validity of iSUMO predictions is further illustrated when examining human proteins that were not part of our training set (of 14 experimental studies), but scored highly in our framework ( Table 3) . Seven of the ten proteins have reported ubiquitination events -a modification that often coincides with SUMOylation. Table 3 were reported in other SUMOylation studies, three of these in a recent highquality dataset by Hendriks et al. (22) . Most excitingly, one protein has been validated by a targeted experimental study -namely DGCR8 whose SUMOylation at lysine 707 stabilizes the protein by preventing ubiquitination at the same residue (63).
Four of the proteins in
In addition to providing high-quality predictions, our study also highlighted several characteristics that appear to be strongly connected to SUMOylation. For example, SUMOylated proteins often bind nucleic acids (e.g. RNA or DNA) and are part of large complexes (Table 2)(22). Specifically, there is strong correlation between SUMOylation, the size of a complex, and the number of subunits that are RNA-binding (Figure 2) . Overall, two fifths (654 of 1,536) of the human RNA-binding proteins are SUMOylated, while this is the case for less than 10% of the total human proteome --suggesting that SUMOylation might play a role specifically in mediating protein-RNA binding, beyond its known function as a facilitator of proteinprotein interactions. Whether SUMOylation modifies the structure of the RNA-binding protein, or affects its surface charge to enable the interaction with the nucleic acid remains subject to future studies.
It is tempting to speculate on the reasons for the prevalence for SUMOylation amongst RNA-binding proteins. Perhaps, with the expansion of RNA-based regulatory pathways in mammals compared to yeast, the well-established, extensive role of SUMOylation of DNA-binding proteins was simply transferred.
Alternatively, SUMOylation might be essential for the correct assembly of large complexes, which are very often involved in RNA-related processes, and the prevalence of SUMOylation for RNA-binding proteins might be a side-effect of its role in complexes. A third intriguing hypothesis arises from two observations: SUMO is one of the most soluble of all known proteins (64) and RNA-binding proteins are major components of RNA-protein granules whose aggregation forms the molecular bases of many neurodegenerative disorders (65). Therefore, SUMOylation may act to prevent such aggregation in these densely packed cellular structures -a hypothesis supported by some experimental work (66).
These considerations also link to the biomedical relevance of SUMOylation, in particular with respect to neuronal diseases (67-69). Indeed, we find that abnormalities of the nervous system amongst SUMOylated proteins (HPO (70), p-value < 1E-7). Further, one of the highest-scoring iSUMO predictions in human, NUFIP1, interacts with a major neuronal regulator protein, the Fragile X Mental Retardation protein 1 (FXR1), and might therefore be linked to this neuronal disease ( Table 3) . 
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